American Association for Cancer Research
Browse
10559965epi131384-sup-matsmetstabs1-2fig1.pdf (99 kB)

Supplementary Materials and Methods, Supplementary Figure 1, Supplementary Tables 1 - 2 from Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines

Download (99 kB)
journal contribution
posted on 2023-03-31, 13:40 authored by Saro H. Armenian, Sarah K. Gelehrter, Tabitha Vase, Rajkumar Venkatramani, Wendy Landier, Karla D. Wilson, Claudia Herrera, Leah Reichman, John-David Menteer, Leo Mascarenhas, David R. Freyer, Kalyanasundaram Venkataraman, Smita Bhatia

PDF file - 98KB, Supplementary Figure 1: Visualization of Data Normalization. Supplementary Table 1: Description of Metabolon QC Samples. Supplementary Table 2: Metabolon QC Standards.

History

ARTICLE ABSTRACT

Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose. The mechanism by which this occurs has not been fully elucidated. Metabolomics, the comprehensive profile of small-molecule metabolites, has the potential to provide insight into the pathogenesis of disease states and discover diagnostic markers for therapeutic targets. We performed echocardiographic testing and blood plasma metabolomic analyses (8 pathways; 354 metabolites) in 150 asymptomatic childhood cancer survivors previously treated with anthracyclines. Median time from cancer diagnosis to study participation was 12.4 years (2.6–37.9 years); 64% were treated for a hematologic malignancy; median anthracycline dose was 350 mg/m2 (25–642 mg/m2). Thirty-five (23%) participants had cardiac dysfunction—defined as left ventricular end-systolic wall stress >2SD by echocardiogram. Plasma levels of 15 compounds in three metabolic pathways (carbohydrate, amino acid, and lipid metabolism) were significantly different between individuals with cardiac dysfunction and those with normal systolic function. After adjusting for multiple comparisons, individuals with cardiac dysfunction had significantly lower plasma carnitine levels [relative ratio (RR), 0.89; P < 0.01] in relation to those with normal systolic function. These findings may facilitate the development of primary prevention (treatment of carnitine deficiency before/during anthracycline administration) and secondary prevention strategies (screening and treatment in long-term survivors) in patients at highest risk for CHF. Cancer Epidemiol Biomarkers Prev; 23(6); 1109–14. ©2014 AACR.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC